Business Context and Reporting Period
This Form 8-K was filed by Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) on April 13, 2021. The report details the closing of the Company's Initial Public Offering (IPO) and the concurrent adoption of amended and restated corporate governance documents. Note: The request metadata lists "Onkure Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Reneo Pharmaceuticals, Inc.
Key Financial Metrics
- Capital Raised: The Company sold 6,250,000 shares of Common Stock at a public price of $15.00 per share.
- Gross Proceeds: Approximately $93.8 million (before deducting underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters were granted a 30-day option to purchase up to an additional 937,500 shares.
- Operating Metrics: The filing does not provide revenue, profit, cash flow, margins, or debt figures for the reporting period.
Material Changes
The primary material change reported is the transition from a private to a public company via the IPO closing on April 13, 2021. Additionally, the Company filed an Amended and Restated Certificate of Incorporation and adopted Amended and Restated Bylaws effective immediately prior to the IPO closing.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies. The document focuses strictly on the mechanics of the IPO and corporate governance updates. Investors are referred to the Prospectus filed on April 9, 2021, for a description of capital stock provisions and further details.
Key Facts for Investor Verification
- Verify the final net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds ($93.8 million) are stated.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 937,500 shares.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for specific governance provisions.
- Consult the Prospectus (File No. 333-254534) for detailed risk factors and use of proceeds not included in this 8-K.